Viral vector-mediated gene therapies

Current Opinion in Neurology

Volumn 28, Issue 5, 2015, Pages 522-527

  Hollinger, Katrin ^a   Chamberlain, Jeffrey S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated viruses; Cas9 CRISPR; Duchenne muscular dystrophy; Dystrophin

Indexed keywords

DYSTROPHIN; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; DUCHENNE MUSCULAR DYSTROPHY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; NONHUMAN; REVIEW; TISSUE SPECIFICITY; TRANSGENE; VIRUS CAPSID; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; MUSCULAR DYSTROPHY, DUCHENNE; PROCEDURES; THERAPEUTIC USE;

DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84941787901     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000241     Document Type: Review

References (38)

1. Emery AE. The muscular dystrophies. Lancet 2002; 359:687-695.
2. Roberts RG, Coffey AJ, Bobrow M, Bentley DR. Exon structure of the human dystrophin gene. Genomics 1993; 16:536-538.
3. Abmayr S, Chamberlain J. The structure and function of dystrophin. In: Winder SJ, editor. Molecular Mechanisms of Muscular Dystrophies. Georgetown: Landes Biosciences; 2006. pp. 14-34.
4. Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002; 8:253-261.
5. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010; 363:1429-1437.
6. Seto JT, Bengtsson NE, Chamberlain JS. Therapy of genetic disorders-novel therapies for Duchene muscular dystrophy. Curr Pediatr Rep 2014; 2:102-112.
7. Odom GL, Gregorevic P, Allen JM, Chamberlain JS. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther 2011; 19:36-45.
8. Lostal W, Kodippili K, Yue Y, Duan D. Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum Gene Ther 2014; 25:552-562.
9. Koo T, Popplewell L, Athanasopoulos T, Dickson G. Triple trans-splicing adenoassociated virus vectors capable of transferring the coding sequence for fulllength dystrophin protein into dystrophic mice. Hum Gene Ther 2014; 25:98-108.
10. Pan X, Yue Y, Zhang K, et al. AAV-8 is more efficient than AAV-9 in transducing neonatal dog heart. Hum Gene Ther Methods 2015; 26:54-61.
11. Arnett AL, Konieczny P, Ramos JN, et al. Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. Mol Ther Methods Clin Dev 2014; 1:14038.
12. Bello A, Chand A, Aviles J, et al. Novel adeno-associated viruses derived from pig tissues transduce most major organs in mice. Sci Rep 2014; 4:6644.
13. Davis AS, Federici T, Ray WC, et al. Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 2015; 76:216-225; discussion 25.
14. Münch RC, Muth A, Muik A, et al. Off-target-free gene delivery by affinitypurified receptor-targeted viral vectors. Nat Commun 2015; 6:6246.
15. Su LT, Gopal K, Wang Z, et al. Uniform scale-independent gene transfer to striated muscle after transvenular extravasation of vector. Circulation 2005; 112:1780-1788.
16. White JD, Thesier DM, Swain JB, et al. Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther 2011; 18:546-552.
17. Gregorevic P, Schultz BR, Allen JM, et al. Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Mol Ther 2009; 17:1427-1433.
18. Chicoine LG, Rodino-Klapac LR, Shao G, et al. Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin alpha2 surrogates. Mol Ther 2014; 22:713-724.
19. Chicoine LG, Montgomery CL, Bremer WG, et al. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther 2014; 22:338-347.
20. Wang Z, Halbert CL, Lee D, et al. Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model. Gene Ther 2014; 21:363-370.
21. Flanigan KM, Campbell K, Viollet L, et al. Antidystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 2013; 24:797-806.
22. Hayashita-Kinoh H, Yugeta N, Okada H, et al. Intraamniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance. Mol Ther 2015; 23:627-637.
23. Odom GL, Gregorevic P, Allen JM, et al. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/ utrophin-deficient mice. Mol Ther 2008; 16:1539-1545.
24. Sonnemann KJ, Heun-Johnson H, Turner AJ, et al. Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med 2009; 6:e1000083.
25. Strimpakos G, Corbi N, Pisani C, et al. Novel adeno-associated viral vector delivering the utrophin gene regulator jazz counteracts dystrophic pathology in mdx mice. J Cell Physiol 2014; 229:1283-1291.
26. Belanto JJ, Mader TL, Eckhoff MD, et al. Microtubule binding distinguishes dystrophin from utrophin. Proc Natl Acad Sci U S A 2014; 111:5723-5728.
27. Lai Y, Zhao J, Yue Y, et al. Partial restoration of cardiac function with PDZ nNOS in aged mdx model of Duchenne cardiomyopathy. Hum Mol Genet 2014; 23:3189-3199.
28. Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther 2015; 23:192-201.
29. Winbanks CE, Weeks KL, Thomson RE, et al. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. J Cell Biol 2012; 197:997-1008.
30. Rodino-Klapac LR, Janssen PM, Shontz KM, et al. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. HumMol- Genet 2013; 22:4929-4937.
31. Le Guiner C, MontusM, Servais L, et al. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol Ther 2014; 22:1923-1935.
32. Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. Multiplex CRISPR/Cas9- based genome engineering from a single lentiviral vector. Nucleic Acids Res 2014; 42:e147.
33. Li HL, Fujimoto N, Sasakawa N, et al. Precise correction of the dystrophin gene in Duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Rep 2015; 4:143-154.
34. Ousterout DG, Kabadi AM, Thakore PI, et al. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol Ther 2015; 23:523-532.
35. Long C, McAnally JR, Shelton JM, et al. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 2014; 345:1184-1188.
36. Larcher T, Lafoux A, Tesson L, et al. Characterization of dystrophin deficient rats: a new model for Duchene muscular dystrophy. PLoS One 2014; 9:e110371.
37. Nakamura K, Fujii W, Tsuboi M, et al. Generation of muscular dystrophy model rats with a CRISPR/Cas system. Sci Rep 2014; 4:5635.
38. Chen Y, Zheng Y, Kang Y, et al. Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. Hum Mol Genet 2015; 24:3764-3774.